Results 21 to 30 of about 56,924 (160)

Stromal fibroblast growth factor 2 reduces the efficacy of bromodomain inhibitors in uveal melanoma

open access: yesEMBO Molecular Medicine, 2019
Alterations in transcriptional programs promote tumor development and progression and are targetable by bromodomain and extraterminal (BET) protein inhibitors.
Vivian Chua   +12 more
doaj   +1 more source

Epi-drugs in combination with immunotherapy: a new avenue to improve anticancer efficacy [PDF]

open access: yes, 2017
Immune checkpoint factors, such as programmed cell death protein-1/2 (PD-1, PD-2) or cytotoxic T lymphocyte-associated antigen-4 (CTLA-4) receptors, are targets for monoclonal antibodies (MAbs) developed for cancer immunotherapy.
Mai, Antonello   +3 more
core   +1 more source

Targeting translation initiation by synthetic rocaglates for treating MYC-driven lymphomas. [PDF]

open access: yes, 2020
MYC-driven lymphomas, especially those with concurrent MYC and BCL2 dysregulation, are currently a challenge in clinical practice due to rapid disease progression, resistance to standard chemotherapy, and high risk of refractory disease.
Bi, Chengfeng   +15 more
core   +1 more source

Adenoid cystic carcinoma: emerging role of translocations and gene fusions. [PDF]

open access: yes, 2016
Adenoid cystic carcinoma (ACC), the second most common salivary gland malignancy, is notorious for poor prognosis, which reflects the propensity of ACC to progress to clinically advanced metastatic disease.
Brait, Mariana   +5 more
core   +6 more sources

Regulation of inflammatory genes in decidual cells: Involvement of the bromodomain and extra-terminal family proteins.

open access: yesPLoS ONE, 2023
The decidua undergoes proinflammatory activation in late pregnancy, promoting labor. Bromodomain and Extra-Terminal (BET) family proteins interact with acetylated histones and may control gene expression in inflammation.
Sandeep Ajgaonkar   +3 more
doaj   +1 more source

Bromodomain and Extra-Terminal (BET) Domain Protein Inhibitors for Solid Tumor Cancers [PDF]

open access: yesJournal of Immunotherapy and Precision Oncology, 2020
The bromodomain and extraterminal (BET) domain protein family is involved in the process of transcription of genetic information. The BET protein family includes BRD2, BRD3, BRD4, and bromodomain testis-specific protein.
Martin V. Nguyen   +2 more
doaj   +1 more source

New synthetic routes to Triazolo-benzodiazepine analogues:expanding the scope of the bump-and-hole approach for selective Bromo and Extra-Terminal (BET) bromodomain inhibition [PDF]

open access: yes, 2015
We describe new synthetic routes developed toward a range of substituted analogues of bromo and extra-terminal (BET) bromodomain inhibitors I-BET762/JQ1 based on the triazolo-benzodiazepine scaffold.
Alessio Ciulli   +5 more
core   +4 more sources

Natural killer cell response to chemotherapy-stressed cancer cells: Role in tumor immunosurveillance. [PDF]

open access: yes, 2017
Natural killer (NK) cells are innate cytotoxic lymphoid cells that actively prevent neoplastic development, growth, and metastatic dissemination in a process called cancer immunosurveillance.
Borrelli, Cristiana   +5 more
core   +1 more source

Roles of reconstituted high-density lipoprotein nanoparticles in cardiovascular disease: A new paradigm for drug discovery [PDF]

open access: yes, 2020
Epidemiological results revealed that there is an inverse correlation between high-density lipoprotein (HDL) cholesterol levels and risks of atherosclerotic cardiovascular disease (ASCVD).
Huang, Hui   +3 more
core   +2 more sources

Dual inhibition of BET and HAT/p300 suppresses colorectal cancer via DR5- and p53/PUMA-mediated cell death

open access: yesFrontiers in Oncology, 2022
BackgroundColorectal cancer (CRC) frequently has a dysregulated epigenome causing aberrant up-regulation of oncogenes such as c-MYC. Bromodomain and extra-terminal domain (BET) proteins and histone acetyltransferases (HAT) are epigenetic regulatory ...
Chaoyuan Kuang   +18 more
doaj   +1 more source

Home - About - Disclaimer - Privacy